<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>Written evidence submitted by University College London (UCL (AMR0039)</title></head><body><div><p style="margin:0pt"><span style="font-family:Calibri; font-size:12pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:center; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by University College London (UCL (AMR0039)</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">UCL has recently convened an AMR network to bring together cross discipline research and expertise in this area from across the university. We are pleased to make a short submission into the Select Committee’s inquiry into antimicrobial resistance drawn from the network, and these issues will be addressed in detail at the upcoming meeting ‘</span><span style="font-family:'Times New Roman'; font-size:11pt">A response to the Department of Health Antibiotic Resistance Strategy’</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">1</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">How has antimicrobial resistance developed in the past decade?</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; orphans:0; padding-left:0.95pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">As the strategy highlights, resistance has developed as result of inadequate control measures and inappropriate use of antibiotics. Whilst the incubator environment of hospitals has driven this in the domestic setting, it is important not to overlook the global drivers for selection of resistance in failing healthcare systems (see paragraph 3 below), and within society in general, which then serve as reservoirs for dissemination of antibiotic resistance associated with increased international mobility. </span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">What are the gaps in our knowledge about antimicrobial resistance?</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; orphans:0; padding-left:0.95pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">At a fundamental level there is a paucity of knowledge with respect to the precise mechanisms by which antibiotic resistance becomes fixed in a bacterial population and the distinction between events in the microbiome of an individual patient and how that interacts with the panbiome of the host community. Thus, the parameters that describe the impact of emergent resistance in an individual patient leading to fixation of resistance in a wider bacterial community need to be defined. Once defined, these will inform the design of health interventions.</span></li></ol><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; orphans:0; padding-left:0.95pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">We would highlight the risks associated with the emergence of antibiotic resistance in poorly controlled or failing healthcare systems, exemplified by the emergence of MDR-TB in the Former Soviet Union and more recently the spread of multiresistant Gram negative infection, particularly in Italy and Greece but also throughout the wider European Union, which is causing a high level of concern. The spread appears to be related to poor infection control and sustained overuse of antibiotics. However, at present, little is known about the mode of transmission of these pathogens and the relationship with the environment. We would therefore suggest that these gaps in our knowledge need urgent attention. </span></li></ol><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; orphans:0; padding-left:0.95pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Poor cleaning and equipment design that impedes cleaning contribute to the risks and we also require a better understanding of how these problems can be address and overcome.  Although so far in UK the emergence of multiresistant Gram negative organisms has been relatively limited, they are appearing in the private hospitals catering for overseas clients which may serve as a point source for further dissemination and thus are a significant cause for concern. We suggest that a survey of antimicrobial resistance in private hospitals is needed to prevent spread within UK and we would urge the Committee to consider this when making its recommendations</span></li></ol><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; orphans:0; padding-left:0.95pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Fundamental knowledge of the transmission mechanisms, in terms of both the transmission of DNA encoding the resistance proteins between different bacteria and also the transmission of the bacteria between different humans, needs to accompany (and should be used to inform) changes in behavior and practice in order to fully address the problem of resistance.  </span></li></ol><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="6" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; orphans:0; padding-left:0.95pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">As the Strategy highlights, antimicrobial research is limited by the lengthy timeline and cost of introduction of new agents. We note that the British Society for Antimicrobial Chemotherapy (BSAC) is attempting to rectify that lack of progress in its current antimicrobial campaign, which is welcome. The pipeline for new antibiotic development is weak and is not being carried out in a </span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:7.33pt; font-style:italic; vertical-align:super">1</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> </span><span style="font-family:'Times New Roman'; font-size:10pt; font-style:italic">D</span><span style="font-family:'Times New Roman'; font-size:10pt; font-style:italic">etails at</span><span style="font-family:'Times New Roman'; font-size:10pt; font-style:italic">: </span><a href="http://www.eventbrite.com/event/9047052979"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:10pt; font-style:italic; text-decoration:underline">http://www.eventbrite.com/event/9047052979</span></a></p><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">nationally coherent manner, with little interest from pharmaceutical companies and limited routes for the development of lead compounds developed in academic settings. We note the contribution of various Research Council schemes and the IMI initiative; however, whilst important these are not sufficient: sustained investment in all stages of the pipeline is required to ensure the flow of new compounds from concept to medicine. </span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Is there sufficient research and investment into new antibiotics or other treatments and methods to ensure continued protection against infection? If not, how could this be rectified?</span></p><p style="margin:0pt 0pt 0pt 24pt; orphans:0; text-align:justify; text-indent:-24pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="7" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; orphans:0; padding-left:0.95pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">It is a well rehearsed argument that our armoury of antimicrobial compounds is limited and this is exacerbated by the extent of cross resistance and shared targets that the current compounds have. There is a requirement for increased fundamental research to identify new target pathways and mechanisms for antimicrobial activity. This needs to be matched by an effective drug development pipeline that allows development of lead compounds. It is essential that regulatory and legal barriers are minimized to ensure rapid delivery of compounds to clinical use.</span></li></ol><p style="margin:0pt 0pt 0pt 24pt; orphans:0; text-align:justify; text-indent:-24pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">What measures (including behavioural change) have been most effective in controlling the spread of resistant pathogens, and could such measures be used to control other pathogens?</span></p><p style="margin:0pt 0pt 0pt 24pt; orphans:0; text-align:justify; text-indent:-24pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="8" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; orphans:0; padding-left:0.95pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">On the whole, antibiotic resistance is not a phenotype that changes the transmission of a pathogen. Thus, measures in place to control drug resistant organisms will also minimize transmission of drug sensitive organisms. Of course, the reverse is also true and control of wild type or drug sensitive organisms will lead to generalized reduction in pathogen burden in the community.</span></li></ol><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="9" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; orphans:0; padding-left:0.95pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">We note an example of a successful intervention to achieve behavior change, in the form of the Clean Your Hands campaign, which was deployed in UK hospitals from 2004-11 to increase the hand hygiene of hospital staff through a number of specific and targeted interventions to change behavior. An evaluation of the campaign found that giving 1-1 feedback led to staff being 13-18% more likely to clean their hands</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">2</span><span style="font-family:'Times New Roman'; font-size:11pt"> and that the targeted interventions which were deployed resulted in a tripling in the use of soap and alcohol to clean hands and reductions in MRSA bacteraemia and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">C. difficile</span><span style="font-family:'Times New Roman'; font-size:11pt"> infection rates</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">3</span><span style="font-family:'Times New Roman'; font-size:11pt">.  (Further information available on request.) This example emphasises the importance of ensuring that behavioural change interventions are based on an appropriate diagnosis of the particular aspects of behaviour which require change and are then specifically targeted to achieve this.</span></li></ol><p style="margin:0pt 0pt 0pt 24pt; orphans:0; text-align:justify; text-indent:-24pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">What global coordination and action is required to fight antimicrobial resistance and is the UK contributing enough towards cross-border initiatives?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">&#xa0;</span></p><ol start="10" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">A global perspective is essential and full participation in global surveillance networks is critical to protection of the UK. This must be outward looking; support for resource-poor communities in their efforts to monitor and control infection is fundamental to the protection of the UK.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">What are the strengths and weaknesses of the Government’s 2013-2018 strategy for tackling antimicrobial resistance? What changes might be made to further strengthen the Government’s action plan?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Behaviour change</span></p><ol start="11" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">We suggest that consideration of behavior change is vital in tackling AMR and will be crucial to the success of the Government’s strategy, particularly as regards the key areas of improving infection prevention and control practices, optimizing prescribing practice and improving public</span></li></ol><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:8pt; font-style:italic; vertical-align:super">2</span><span style="font-family:'Times New Roman'; font-size:9pt; font-style:italic">Stone, Fuller, Savage, Cookson et al, BMJ, 2012.</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:6pt; font-style:italic; vertical-align:super">3</span><span style="font-family:'Times New Roman'; font-size:10pt; font-style:italic">Fuller, Michie, Savage, McAteer et al, PLoS One, 2012.</span></p><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt"> engagement. We emphasise that changing behavior requires interventions at many levels (population, community, individuals) and which are simultaneous and consistent. Whilst the AMR </span></p><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">strategy mentions a number of interventions which represent a positive way forward (such as education, training, encouragement, audit, and guidelines), it is not always clear how the strategy will ensure that the appropriate interventions are made on a multi-level, concurrent and consistent basis. The strategy should ensure that behavioural change interventions are designed on the basis of a thorough diagnosis of behavioural ‘problems’ and are applied in a clearly targeted way to address specific diagnoses – </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">ie</span><span style="font-family:'Times New Roman'; font-size:11pt"> there is unlikely to be a ‘blanket’ behaviour change intervention. There should also, as the strategy does recognize, be recurrent evaluation of the impact of such interventions.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Engagement with the antibiotic development pipeline</span></p><ol start="12" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">As indicated above, the drug development pipeline needs to be accelerated and a key constraint is the regulatory environment for clinical trials. Whilst we acknowledge that patient safety must take precedence, the risks associated with emergence of MDR organisms require increased flexibility from the regulators. This is most evident with respect to development of treatments for tuberculosis in which the study endpoints are typically at 12-18 months after completion of treatment. Whilst tuberculosis may be considered an extreme example, similar issues occur across all anti-infectives and these must be addressed with innovative study designs, for which approval is difficult to obtain</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">4</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span></li></ol><p style="margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Resources to support implementation</span></p><ol start="13" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 14.2pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">We note with concern that no additional resources have been allocated to support the implementation of the Government’s 2013-18 AMR strategy, although establish funding streams are reported. We recognize that there is currently a considerable constraint on public spending which means that providing additional resources may be challenging. However, we argue that given the current context of major cuts in the NHS and wider health sector coupled with the restructuring of the Health Protection Agency and Public Health England, it is likely to be very difficult to effectively implement the strategy without any support. We would therefore suggest that the Government should consider providing dedicated resource to support the implementation of the 2013-18 strategy.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">November 2013</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:12pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:12pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:12pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:12pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:12pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:12pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:12pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:12pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:12pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:12pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:12pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:12pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:12pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:12pt">&#xa0;</span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:100%"><tr><td style="vertical-align:top"><p style="margin:0pt"><span style="font-family:Calibri; font-size:8pt; font-style:italic; vertical-align:super">4</span><span style="font-family:Calibri; font-size:12pt; font-style:italic"> </span><a href="http://www.ncbi.nlm.nih.gov/pubmed/22448027"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:9pt; font-style:italic; text-decoration:underline">Innovative trial designs are practical solutions for improving the treatment of tuberculosis.</span></a></p></td></tr><tr><td style="vertical-align:top"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:9pt; font-style:italic">Phillips PP, Gillespie SH, Boeree M, Heinrich N, Aarnoutse R, McHugh T, Pletschette M, Lienhardt C, Hafner R, Mgone C, Zumla A, Nunn AJ, Hoelscher M. </span></p></td></tr><tr><td style="vertical-align:top"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:9pt; font-style:italic">J Infect Dis</span><span style="font-family:'Times New Roman'; font-size:9pt; font-style:italic">. 2012 May 15;205 Suppl 2:S250-7. doi: 10.1093/infdis/jis041. Epub 2012 Mar 22.</span></p></td></tr></table><p style="margin:0pt"><a name="_GoBack"></a><span style="font-family:Calibri; font-size:12pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:12pt">&#xa0;</span></p></div></body></html>